Nanobiotix SA (EPN:NANO) has been invited to give two presentations to the Society for Immunotherapy of Cancer (SITC) conference this month for its flagship NBTXR3 treatment.
A pioneering approach to cancer, nanoparticles are injected directly into solid tumours to amplify the effects of shrinking treatment.
It has already demonstrated success tackling soft tissue sarcoma, a cancer that affects muscle, fat and blood vessels.
The company currently has seven clinical trials underway but is also exploring NBTXR3’s potential in immuno-oncology in combination therapies.
An investigational new drug application is being prepared for a combination trial in the US with checkpoint inhibitors, another of promising research in cancer treatment.
In January, meanwhile, first results from a phase I/II trial in liver cancer patients are expected and will be presented to the ASCO GI conference.